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MaAortic stenosis is a common, potentially fatal condition that is set to become an increasing public health burden. Once
symptoms develop, there is an inexorable deterioration with a poor prognosis. Despite this, there are no medical ther-
apies capable of modifying disease progression, and the only available treatment is aortic valve replacement, to which
not all patients are suited. Conventional teaching suggests that aortic stenosis is a degenerative condition whereby “wear
and tear” leads to calcium deposition within the valve. Although mechanical stress and injury are important factors, it
is becoming increasingly appreciated that aortic stenosis is instead governed by a highly complex, regulated pathological
process with similarities to skeletal bone formation. This review discusses the pathophysiology of aortic stenosis with an
emphasis on the emerging importance of calciﬁcation, how this can be visualized and monitored using noninvasive
imaging, and how our improved knowledge may ultimately translate into novel disease-modifying treatments.
(J Am Coll Cardiol 2015;66:561–77) © 2015 by the American College of Cardiology Foundation.A ortic stenosis is the most common form ofvalve disease in the Western world and isset to become an ever-increasing public
health burden (1,2). Despite this, there are no medical
therapies to halt or delay disease progression, and the
only available treatment is aortic valve replacement
or implantation, to which not all patients are suited.
There is, therefore, a major unmet clinical need to
identify pharmacological treatments capable of modi-
fying this disease process.
Aortic stenosis was long considered to be a
degenerative condition whereby “wear and tear”
resulted in progressive calcium formation within the
valve. Although mechanical stress and injury remain
central to its pathophysiology, emerging evidence has
indicated that aortic stenosis develops as part of a
highly complex and tightly regulated series of pro-
cesses, each of which may be amenable to medical
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and inﬂammation, with many similarities to athero-
sclerosis, and a later propagation phase where pro-
calciﬁc and pro-osteogenic factors take over and
ultimately drive disease progression (Figure 1) (4).
This review discusses the pathophysiology of aortic
stenosis, with an emphasis on the emerging impor-
tance of calciﬁcation, how this can be imaged
with modern noninvasive techniques, and how our
improved knowledge might ultimately lead to the
development of novel therapies.
PATHOLOGY OF AORTIC STENOSIS
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ABBR EV I A T I ON S
AND ACRONYMS
BMP = bone morphogenetic
protein
CT = computed tomography
FDG = ﬂuorodeoxyglucose
LDL = low-density lipoprotein
OPG = osteoprotegerin
PET = positron emission
tomography
RANK = receptor activator of
nuclear factor kappa B
RANKL = receptor activator of
nuclear kappa B ligand
TGF = transforming growth
factor
VIC = valvular interstitial cell
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562mobile structure (3). In aortic stenosis, these
leaﬂets become thickened, ﬁbrosed, and
calciﬁed, resulting in reduced leaﬂet mobility
and progressive valvular obstruction.
The early stages of aortic stenosis are in
many ways similar to atherosclerosis.
Indeed, the 2 conditions share many common
risk factors, with large longitudinal studies
consistently demonstrating that the incidence
of aortic stenosis is linked to factors such as
smoking, age, and hypertension (5–7). As in
atherosclerosis, endothelial damage due to
increased mechanical stress and reduced
shear stress is believed to be the initiating
injury, perhaps best illustrated by bicuspid
valve disease. The characteristic 2-leaﬂet
structure of these valves results in less efﬁ-
cient dissipation of mechanical stress andaccelerated endothelial damage, so that patients
almost universally develop aortic stenosis and
display more rapid disease progression (8).
Following endothelial damage, the same lipids
implicated in atherosclerosis inﬁltrate the valve, in
particular, lipoprotein(a) and oxidized low-density
lipoprotein (LDL) cholesterol. Consequently, obser-
vational studies have identiﬁed cholesterol and its
related lipoproteins as independent risk factors for
the development of aortic stenosis (5–7,9). Indeed, a
strong genome-wide association was recently estab-
lished between a single-nucleotide polymorphism in
the locus of lipoprotein(a) and the incidence of aortic
valve calciﬁcation (10). Progressive endothelial injury
and lipid oxidization then establishes an inﬂamma-
tory response within the valve that is characterized
predominantly by inﬁltration of macrophages, but
also involves T lymphocytes and mast cells (11).
At this early stage, regions of stippled micro-
calciﬁcation that colocalize with sites of lipid depo-
sition are observed (11). The formation of these
microcalciﬁcations may be mediated by cell death
and the release of apoptotic bodies in these areas.
Such apoptotic bodies are similar to the matrix vesi-
cles found in bone, which contain the prerequisite
components for calcium crystal deposition (including
calcium and inorganic phosphate ions) and facilitate
the formation of needle-like crystals of hydroxyapa-
tite (4,12). In bone, as these hydroxyapatite crystals
expand, they pierce the outer membrane of the
vesicle and become exposed to the extracellular
environment, thereby forming nucleation sites for
further calcium deposition. It is probable that similar
processes also occur within the valve (13). Further-
more, hydroxyapatite deposition evokes further pro-
inﬂammatory responses from macrophages, creatinga positive feedback loop of calciﬁcation and inﬂam-
mation in the early stages of disease (14). It seems
likely that these mechanisms underlie early calcium
formation in aortic stenosis and its association with
lipid and inﬂammation.
The apparent link between lipid, inﬂammation,
and calciﬁcation in these early stages and the patho-
logical similarities with atherosclerosis led to the
hypothesis that statins might be beneﬁcial in patients
with aortic stenosis. This was supported by encour-
aging nonrandomized human data (15) and studies in
hypercholesterolemic animal models demonstrating
that lipid deposition and oxidative stress precede the
conversion of valvular interstitial cells to those with
an osteoblastic phenotype, and that this process is
inhibited by atorvastatin (16,17). However, when
statins were formally tested in 3 independent ran-
domized controlled trials of patients with aortic ste-
nosis, each demonstrated a failure of this therapy to
halt or retard aortic stenosis progression, despite
reducing the serum LDL cholesterol concentrations
by more than one-half (18–20). This has led in-
vestigators to re-examine the pathophysiology un-
derlying aortic stenosis and to the realization that
although inﬂammation and lipid deposition may be
important in establishing the disease (the initiation
phase), the later stages are instead characterized by
an apparently self-perpetuating cycle of calcium for-
mation and valvular injury (the propagation phase)
(4). Indeed, once this propagation phase has become
established, disease progression is dictated neither by
inﬂammation nor by lipid deposition, but rather by
the relentless accumulation of calcium in the valve
leaﬂets. This may explain the failure of statins to
modify disease progression in aortic stenosis, which
commonly presents beyond the initiation phase.
Moreover, there is some data that statins may even be
procalciﬁc in the vasculature (21,22).
CALCIFICATION AND THE PROPAGATION PHASE. Ske-
letal bone formation is characterized by the initial
deposition of collagen matrix, which provides a
scaffold upon which progressive calciﬁcation can
develop. With time, this calcium acquires a more or-
dered crystalline structure until the characteristic
features of lamellar bone are ﬁnally observed. Similar
structural processes are believed to occur in the aortic
valve, with many of the same cell mediators and
proteins implicated (23). Indeed, in aortic stenosis,
collagen is deposited in anticipation of the procalciﬁc
processes that subsequently dominate. This ﬁbrotic
process within the valve may be mediated, in part,
by reduced nitric oxide expression following endo-
thelial injury (24); however, the renin-angiotensin
system (RAS) is also believed to play a central
FIGURE 1 The Pathophysiology of Aortic Stenosis
8. Apoptotic bodies
form nucleation sites
for calcium deposition
Apoptotic
Body
7. Apoptosis of
VICs and
Inflammatory
Cells
4. RANKL Binding
to RANK
RANKL RANK
Valve
Interstitial Cell
(VIC)
5. Osteoblastic
Differentiation
•  BMP
•  Notch
•  RANK/RANKL
Osteoblast
6. Calcium deposition
on a collagen scaffold
9. Calcium
Ortho-phosphate
11. Activation,
differentiation & apoptosis
(Wnt/catenin & ENPP1)
1. Endothelial
injury 2. Infiltration of
Inflammatory Cells
and Lipid deposition
Macrophage T lymphocyte
Oxidized
LDL
Lipoprotein
(a)
Mast cell
3. Release of Inflammatory Mediators
Injury
10. Increased
mechanical
stress and injury
INITIATION PHASE PROPAGATION PHASE
Initiation phase: endothelial injury (1) facilitates the inﬁltration of oxidized lipids and inﬂammatory cells (2) into the valve and the release of proinﬂammatory medi-
ators (3). These trigger the very early stages of valve calciﬁcation. The propagation phase: these proinﬂammatory processes subsequently induce VICs to undergo
osteogenic differentiation (5) via several different mechanisms, including the binding of RANKL to RANK (4). Differentiated cells within the aortic valve ﬁrst lay down a
collagen matrix and other bone-related proteins causing valvular thickening and stiffening before producing calcium (6). Additionally, apoptotic remnants of some VICs
and inﬂammatory cells (7) create a nidus for apoptosis-mediated calciﬁcation (8). Calciﬁcation of the valve (9) induces compliance mismatch, resulting in increased
mechanical stress and injury (10). This results in further calciﬁcation via osteogenic differentiation and apoptosis (11). Hence, a self-perpetuating cycle of calciﬁcation,
valve injury, apoptosis, and osteogenic activation is established that drives the propagation phase of the disease. BMP ¼ bone morphogenetic protein; ENPP1 ¼
ectonucleotide pyrophosphate 1; LDL ¼ low-density lipoprotein; RANK ¼ receptor activator of nuclear kappa B; RANKL ¼ receptor activator of nuclear kappa B ligand;
RAS ¼ renin-angiotensin system; VIC ¼ valvular interstitial cell.
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563role. Angiotensin-converting enzyme (ACE) is up-
regulated in calciﬁc aortic valve disease and is likely
to be delivered to the valve by LDL, its natural vehicle
(25). Here it facilitates the conversion of angiotensin
I to II, which mediates proﬁbrotic effects via the
angiotensin II type 1 (AT1) receptor. Although angio-
tensin II is also able to mediate antiﬁbrotic and anti-
inﬂammatory effects via angiotensin II type 2 (AT2)
receptors, differential expression of these re-
ceptors in favor of AT1 has been demonstrated in
calciﬁed aortic valves, so that a proﬁbroticproﬁle dominates. Likewise, although angiotensin-
converting enzyme type 2 (ACE-2) exerts antiﬁbrotic
and anti-inﬂammatory inﬂuences via the Ang1-7/Mas
pathway, this pathway is down-regulated in calciﬁed
aortic stenosis, with reduced expression of both
ACE-2 and Mas receptors in calciﬁed valves compared
with control subjects (26). Increased RAS expression
is, therefore, implicated in the development of
ﬁbrosis within the valve. On a systemic level, RAS
is implicated in the development of hyperten-
sion, which often accompanies aortic stenosis and
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564may accelerate its progression given the increased
mechanical stress it imposes upon the valve (27).
Beyond this initial ﬁbrosis, valvular calciﬁcation in
aortic stenosis ultimately dominates and appears
dependent upon the presence of osteoblast-like cells
that develop an osteogenic phenotype. In support of
this hypothesis, gene-proﬁling studies have demon-
strated increased valvular expression of several
osteoblast-speciﬁc proteins, including the Cbfa1/
Runx2 transcription factor, essential for osteoblastic
differentiation and regulation of osteoblast function
(28,29). A number of other extracellular matrix pro-
teins closely associated with osteoblast function and
more commonly associated with skeletal bone for-
mation are also up-regulated in calciﬁc aortic valves.
These include osteopontin and bone sialoprotein,
which are facilitators of the attachment of osteoblasts
to the bone matrix, and demonstrate up to a 7-fold
elevation in gene expression at sites of developing
calciﬁcation (30,31). Importantly, valvular ossiﬁcation
also appears to be dependent upon angiogenesis,
supporting the hypothesis that this is an active,
highly regulated, pathological process (23).
The source of osteoblast-like cells within the
aortic valve remains controversial. In vitro, multiple
cell types present in the vasculature are capable of
undergoing differentiation into those with an
osteoblast-like phenotype. The most likely candi-
date appears to be the myoﬁbroblast, a highly
plastic cell that is also commonly referred to as the
valve interstitial cell (VIC) (32). The differentiation
of this cell into an osteoblast phenotype is not fully
characterized, but appears to be a central step in the
development of aortic stenosis and is regulated by a
rapidly growing list of molecules and complex
pathways. In vivo molecular imaging has demon-
strated that in the early stages of aortic stenosis,
this differentiation appears coordinated by macro-
phages (33,34) via the action of proinﬂammatory
cytokines (interleukin [IL]-1b, IL-6, IL-8, tumor ne-
crosis factor [TNF]-a, insulin-like growth factor-1,
and transforming growth factor [TGF]-b) (4,35,36).
However, in the later stages, this differentia-
tion again appears to be dominated by calciﬁc
pathways, including the Notch, Wnt/b-catenin, and
receptor activator of nuclear factor kappa B (RANK)/
receptor activator of nuclear factor kappa B ligand
(RANKL)/osteoprotegerin (OPG) pathways, which we
discuss here.
Notch belongs to a family of cell surface receptors
(Notch 1 to 4) that are highly expressed in the aortic
valve, playing an important role in its morphological
development (37). Individuals with loss-of-function
mutations in Notch-1 have higher rates ofcardiovascular calciﬁcation and aortic stenosis. In 2
unrelated families with a high incidence of con-
genital aortic valve disease, genome-wide linkage
analysis identiﬁed loss-of-function Notch-1 muta-
tions as the cause (37). In particular, Notch-1 ap-
pears to be important in establishing osteogenic
cells in the valve via the action of bone morphoge-
netic protein (BMP)-2 (38). BMP-2 is a potent oste-
ogenic differentiation factor and part of a family of
multifunctional cytokines belonging to the TGF-b
superfamily. Expression of BMP-2 is increased in
calciﬁed atherosclerotic lesions and aortic valves
(29,39), and it appears to have a central role in the
differentiation of plastic cell populations toward an
osteogenic phenotype. Indeed, exposure of normal
human VICs to BMP-2 induces osteoblastic features
in these cells (40,41). In addition, binding of Wnt to
LDL receptor-related protein 5 receptors may acti-
vate the canonical Wnt/b-catenin pathway that is
also implicated in osteogenic cell differentiation
(42). Similarly, TGF-b1 is able to induce nuclear
translocation of b-catenin and increased Wnt
signaling, stimulating the osteogenic differentiation
of mesenchymal progenitor cells (43). The latter
process can increase in response to mechanical stress
and may therefore explain, in part, the self-
perpetuating and exponential increase in calciﬁca-
tion activity observed once osteogenic differentiation
has occurred and the propagation phase is estab-
lished (Figure 1) (43,44).
Systemic regulators that govern calciﬁcation
activity, both in the bone and in the vasculature,
tightly control calcium homeostasis; consequently,
there is an inverse correlation between bone mineral
density and vascular calciﬁcation. Osteoporosis
is associated with age-independent increases in
vascular calciﬁcation and even cardiovascular mor-
tality (45). A prospective study of 25,639 men and
women demonstrated an inverse correlation between
bone mineral density and incident aortic stenosis
in older women (46). Moreover, other disorders of
bone turnover, including chronic kidney disease
and Paget’s disease, also manifest changes in the
vasculature (47–50). This dichotomy has been termed
the “calciﬁcation paradox” and is likely to be
explained by common pathological pathways having
reciprocal effects on the bone and vasculature
simultaneously.
A potential mechanism for this association lies in
the activity of the RANK/RANKL/OPG pathway
(Figure 2A). In bone, RANKL (a member of the TNF
cytokine family) binds to RANK (a transmembrane
protein expressed on marrow stromal cells and pre-
osteoclasts), acting as a potent inducer of osteoclast
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565differentiation and activity. This drives demineral-
ization of bone, but is policed by osteoprotegerin
(OPG), a soluble decoy receptor, which binds RANKL
and prevents it from activating RANK (Figure 2). In
contrast, RANKL appears to have the opposite effect
on cells in the vasculature, inducing an osteoblastic
phenotype in human VIC cells that results in
increased matrix calciﬁcation, the formation of
calciﬁc nodules, and increased expression of alkaline
phosphatase and osteocalcin (Figure 2A) (51). RANKL
also promotes the osteogenic properties of vascular
smooth muscle cells, once again via the up-regulation
of BMP-2. As a consequence, whilst OPG-deﬁcient
mice develop osteoporosis, they simultaneously
accelerate vascular calciﬁcation in association with
increased expression of RANKL in both regions (52).
A potential explanation for the differential effects of
RANK/RANKL/OPG in these 2 tissues is that in bone
there is an abundance of pre-osteoclasts that favors
the pro-osteoclastic properties of RANKL (36). In
contrast, this pool is absent in the vasculature so that
RANKL’s pro-osteoblastic effects on myoﬁbroblast
and smooth muscle cells predominate.
Imbalances in RANKL/OPG signaling have been
demonstrated in calciﬁc aortic valves. In human
valve tissue taken from patients with aortic stenosis,
immunochemistry revealed less OPG-positive cells in
areas of focal calciﬁcation, whereas western blotting
demonstrated that OPG was not expressed at rele-
vant levels in aortic stenosis, but was detectable in
control subjects. The converse is true of RANKL,
with increased levels observed in stenotic aortic
valves (51). In combination, these data support the
hypothesis that the RANK/RANKL/OPG axis is
implicated in the development of aortic valve calci-
ﬁcation and provide 1 explanation for the link be-
tween aortic valve calciﬁcation and bone mineral
density. Other investigators have suggested that the
differential effects of oxidized LDL might also be of
importance, with this molecule appearing to pro-
mote calciﬁcation and the osteoblastic differentia-
tion of vascular cells in vitro, whilst inhibiting these
processes in a bone-derived pre-osteoblast cell line
(4,53,54).
Fetuin-A is a circulating protein that can
exist in isolation or as a complex with matrix
g-carboxyglutamic acid protein (MGP). Both are
powerful guardians against ectopic calciﬁcation and
simultaneously inhibit many of the procalciﬁc pro-
cesses discussed earlier (55). MGP needs to be both
carboxylated and phosphorylated to be activated, a
process dependent on vitamin K. There is speculation
that use of the vitamin K antagonists, such as couma-
rins, may be associated with increased vascularcalciﬁcation (56). The actions of fetuin-A and MGP
include inhibition of BMP2 and TGF-b, reduction of
apoptosis-mediated calciﬁcation, and direct preven-
tion of calciﬁcation by binding to calcium crystals.
Reduced circulating levels of Fetuin-A and MGP are
thought to explain the vascular calciﬁcation seen with
end-stage renal failure. Moreover, plasma fetuin-A
concentrations are decreased in aortic stenosis
and inversely associated with the rate of disease pro-
gression (57,58). Interestingly, this association was
seen only in older patients (>70 years of age) (59).
Conversely, increased plasma dephosphorylated
(inactive) MGP was a strong independent predictor of
faster stenosis progression, but only in younger pa-
tients (#57 years of age) (60).
WHY DOES CALCIUM BEGET CALCIUM? Once calci-
ﬁcation is established in the valve, it would appear
to initiate further calcium formation. This self-
perpetuating cycle of calciﬁcation and valve injury
appears to be the central driver of disease progres-
sion and the propagation phase of aortic stenosis
(Figure 1).
The mechanism for this may, in part, relate to the
compliance mismatch caused by calciﬁc deposits in
the leaﬂets that results in increased mechanical
stress, injury-induced activation of the Wnt/b-catenin
pathway, and further osteoblast differentiation.
However, it may also be explained by the actions of
membrane-bound ectonucleotidases. These are pro-
duced by VICs and regulate the extracellular pro-
duction of inorganic phosphate (a promoter of
calciﬁcation) and inorganic pyrophosphate, an in-
hibitor of pyrophosphate. Ectonucleotide pyrophos-
phatase 1 (ENPP1) is highly up-regulated in calciﬁc
aortic valve disease, with a polymorphism associated
with increased transcripts of ENPP1 identiﬁed in ste-
notic valves (61). Hydrolysis of extracellular adeno-
sine triphosphate (ATP) by ENPP1 produces a net
increase in inorganic phosphate, thus favoring calci-
ﬁcation and promoting the production of further
ENPP1 in a positive feedback loop (61). Moreover,
because ATP acts as a cell survival signal for VICs via
the P2Y2 receptor, its depletion also triggers apoptosis
of these cells, providing a further key stimulus to
calciﬁcation (61). Finally, loss of P2Y2 signaling
increases the secretion of IL-6, a cytokine that pro-
motes further osteogenic differentiation of VICs via
the actions of BMP (62). Thus, via these multiple
mechanisms, the ectonucleotidase pathway appears
to have a central role in amplifying procalciﬁc pro-
cesses within the valve during the propagation phase
of aortic stenosis.
Given that the pathophysiology and the progres-
sion of aortic stenosis are dominated by calciﬁcation,
FIGURE 2 Mechanisms Underlying the Relationship Between Bone Mineral Density and Valvular Calciﬁcation and Potential Mechanisms
of Action for Denosumab and Bisphosphonates
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FIGURE 2 Continued
Denosumab: Mechanism of Action
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(A) Schematic representation of the differential effects of the RANK/RANKL/OPG axis upon skeletal bone and the calcifying aortic valve. Aortic
valve: binding of RANKL to RANK on valvular interstitial cells induces osteogenic differentiation and calcium deposition. Bone: binding of
RANKL to RANK on osteoclast precursors induces osteoclastic maturation and differentiation, resulting in bone resorption and increased
availability of calcium and phosphate. Osteoprotegerin binds to RANKL, preventing it from binding to RANK, thus reducing both bone
resorption and calcium deposition within the valve. (B) Proposed mechanism of action of bisphosphonates in the treatment of aortic stenosis.
Bisphosphonates reduce the production of inﬂammatory cytokines, thereby reducing osteogenic differentiation of VICs. They also inhibit the
production of matrix metalloproteinases and regulate extracellular mineralization within the vasculature. Simultaneously, the prevention
of bone resorption by bisphosphonates also reduces the availability of procalciﬁc substances. In combination, this is likely to result in reduced
calcium deposition in the valve, along with reduced bone resorption. (C) Proposed mechanism of action of denosumab in the treatment of aortic
stenosis. Binding of denosumab to RANKL prevents its binding to RANK, which inhibits the osteogenic differentiation of valvular interstitial
cells. It simultaneously prevents osteoclast differentiation in the bone, and inhibits bone resorption and availability of procalciﬁc substances.
In combination, this is likely to result in reduced calcium deposition in the valve and reduced bone resorption. OPG ¼ osteoprotegerin; other
abbreviations as in Figure 1.
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567we will next discuss how this process can be imaged
to better understand the pathophysiology of aortic
stenosis, to predict disease progression and clinical
outcomes, and to help develop novel treatments
strategies for this common and potentially fatal
condition.
CLINICAL IMAGING OF
AORTIC VALVE CALCIFICATION
The burden and activity of aortic valve calciﬁcation
can be measured using noninvasive imaging. In
particular, echocardiography, computed tomography
(CT), and positron emission tomography (PET) can all
be used to provide progressively more detailed as-
sessments of the calciﬁc processes occurring withinthe valve (Figure 3). These techniques have not only
informed our understanding as to the importance of
calciﬁcation in aortic stenosis, but have also aided our
ability to assess disease severity and to predict pro-
gression and adverse cardiovascular outcomes. The
latter is of particular importance. Aortic stenosis
progression frequently does not occur in a linear or
predictable manner, making estimation as to when
valve replacement will be required challenging.
Annual or biannual clinical review is generally
required, with serial echocardiography performed to
track progressive valve narrowing. The development
of a noninvasive method capable of predicting the
future natural history of aortic stenosis and the likely
timing of valve surgery would represent a major
advance and help streamline patient care. Given
FIGURE 3 Different Methods for Imaging Calciﬁcation in a Single Subject
With Aortic Stenosis
(A) 2-dimensional echocardiography. (B) CT calcium scoring. (C) CT angiography.
(D) 18F-ﬂuoride PET-CT. CT ¼ computed tomography; PET ¼ positron emission
tomography.
Pawade et al. J A C C V O L . 6 6 , N O . 5 , 2 0 1 5
Calciﬁcation in Aortic Stenosis A U G U S T 4 , 2 0 1 5 : 5 6 1 – 7 7
568the central role that mineralization plays in disease
progression, it is, perhaps, not surprising that as-
sessments of aortic valve calciﬁcation have, to date,
provided the best prediction.
ECHOCARDIOGRAPHY
Echocardiography is a cheap, safe, and widely used
method of assessing aortic stenosis severity in the
clinical setting. International guidelines recommend
grading aortic stenosis severity using the following
hemodynamic echocardiographic assessments: the
peak velocity, the mean gradient, and the aortic valve
area (63). However, echocardiography can also be used
to categorize valves according to their degree of
valvular calciﬁcation into those with no, mild, mod-
erate, and severe calciﬁcation. Indeed, in a series of 128
patients with severe, asymptomatic aortic stenosis,
this semiquantitative assessment provided powerful
prognostic information, acting as a strong indepen-
dent predictor of death or aortic valve replacement
that outperformed the more conventional hemody-
namic measures (64). Although this observation has
been conﬁrmed in another study of 141 asymptomatic
patients (65), the clinical utility of this approach hasbeen limited by disappointing interobserver agree-
ment in grading the calciﬁcation (66,67).
CT CALCIUM SCORING
CT provides a much more detailed, reproducible,
and accurate assessment of the calciﬁc burden in the
aortic valve than echocardiography (66). Using the
same protocols used for coronary calcium scoring,
electrocardiography-gated noncontrast CT can pro-
vide information with respect to the density, vol-
ume, and mass of macroscopic calcium deposits
within the valve (66). However, as in the coronary
arteries, the aortic valve calcium burden is generally
described using Agatston units (AU), which take both
the radiodensity and volume of calcium into ac-
count. In a series of explanted aortic valves, scores
of 500, 1,100, and 2,000 AU approximated to 300,
1,100, and 1,200 mg of aortic valve calcium, respec-
tively (66).
Early studies demonstrated that CT calcium
scoring of the aortic valve could be used as an alter-
native marker of stenosis severity, demonstrating a
good relationship with hemodynamic echocardio-
graphic assessments (66,68,69). However, until
recently, we lacked appropriate thresholds that might
differentiate patients with and without severe aortic
stenosis, thereby limiting its utility (Table 1) (70).
These thresholds are now available as a consequence
of a landmark series of papers published by Clavel
et al. (71–73). Across 3 sites in Europe and North
America, they performed both echocardiography and
CT calcium scoring in 646 patients with moderate or
severe aortic stenosis and good left ventricular func-
tion. In those subjects whose severity of stenosis was
not in doubt on echocardiography (n ¼ 460), the au-
thors examined the optimal CT calcium score for
differentiating moderate from severe aortic stenosis.
Interestingly, female subjects required less calcium to
develop severe hemodynamic stenosis than male
subjects (even after correcting for body surface area
and the left ventricular outﬂow tract area calculated
by echocardiography), so that the optimal thresholds
were found to be 1,275 AU in women and 2,065 AU in
men. These thresholds then appeared to be of use in
adjudicating the severity of the stenosis when echo-
cardiographic markers were discordant. More impor-
tantly, the authors went on to demonstrate that, in a
population of 794 patients, these thresholds pre-
dicted all-cause mortality independent of all other
markers of an adverse prognosis (73). Standard he-
modynamic parameters on echocardiography were
included in this analysis, suggesting that CT can
provide additional, complementary information to
TABLE 1 Studies Attempting to Deﬁne Computed Tomography Calcium Scoring Thresholds for the Diagnosis of Aortic Stenosis
First Author
(Ref. #) Year n
Method and Criteria for Deﬁning
Severe Aortic Stenosis
Calcium Score
Threshold (AU) Sensitivity Speciﬁcity
Positive
Predictive Value
Negative
Predictive Value
Cowell et al. (107) 2003 157 Echocardiography
aortic valve velocity >4 m/s
>3,700 100 50 39 100
Messika-Zeitoun et al. (66) 2004 100 Echocardiography
aortic valve area <1 cm2
>500 100 69 57 100
Koos et al. (74) 2004 72 Cardiac catheter
aortic valve area <1 cm2
>563 85 92 95 77
Clavel et al. (72) 2013 460 Echocardiography
aortic valve area index
#0.6 cm2/m2, mean
gradient $40 mm Hg
>1,274 (women)
>2,065 (men)
86
89
89
80
93
88
79
82
Cueff et al. (108) 2011 179 Echocardiography
aortic valve area <1 cm2
>1,651 82 80 70 88
Cueff et al. (108) 2011 20 Echocardiography
low ﬂow/low gradient severe AS
Aortic valve area <1 cm
and ejection fraction #40%
and mean pressure gradient
#40 mm Hg2
>1,651 95 89 97 80
Values are % unless otherwise indicated.
AS ¼ aortic stenosis; AU ¼ Agatston units.
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569that obtained during routine clinical care, as had
previously been hinted at by earlier studies (Table 2)
(66,73–75).
An expanding body of published data has also
demonstrated the ability of CT calcium scoring to
predict disease progression in aortic stenosis. Initial
studies indicated that the aortic valve CT calcium
score progresses fastest in patients with the highest
baseline calcium burden (76). We have recently
conﬁrmed this predictive ability in a large prospective
study of patients with the full range of calciﬁc aortic
valve disease. The fastest rates of progression were
again observed in subjects with the most advanced
disease. Indeed, a good correlation was observedTABLE 2 Studies Using Aortic Valve Computed Tomography Calcium
First Author (Ref. #) Year n
Duration of
Follow-Up
Messika-Zeitoun et al. (66) 2004 100 2.0  2.3 yrs Event-f
Surviva
ang
or n
Feuchtner et al. (73) 2006 34 18–24 months Major a
Sympto
prog
Cardiac
Utsunomiya et al. (109) 2013 64 29 months Cardiac
Cardiac
and
urge
Clavel et al. (75) 2014 794 3.1  2.6 yrs Mortali
AU ¼ Agatston units; AVC ¼ aortic valve calcium; AVCS ¼ aortic valve calcium score; Abetween the baseline calcium score and disease pro-
gression at 1 year (r ¼ 0.58; 95% conﬁdence interval
[CI]: 0.15 to 0.82; p ¼ 0.01) (77), which strengthened
further after 2 years of follow-up (r ¼ 0.90; 95% CI:
0.84 to 0.93; p < 0.001) (67). Moderate associations
between the baseline CT calcium score and echocar-
diographic measures of disease progression were also
observed (e.g., change in mean gradient; r ¼ 0.40;
95% CI: 0.21 to 0.56; p < 0.001) (67), and very similar
observations were recently reported in a different
patient population (Figure 4) (78).
In summary, CT calcium would, therefore, appear
to be a useful alternative method for grading
disease severity in aortic stenosis, offering powerfulScoring to Predict Outcomes
Outcomes Key Findings
ree survival
l without dyspnea,
ina, syncope, heart failure,
eed for surgery
AVC independently predicted event-free survival, with
an adjusted relative risk of 1.06 (95% CI: 1.02–1.10)
per 100-AU increment (p < 0.001). 5-year event free
survival rate was 90  4% for those with AVC <500 AU
vs. 29  14% for those with AVC $500 AU (p < 0.0001).
dverse clinical event
ms due to hemodynamic
ression
death
AVC strongest predictor of a major adverse clinical event
(p < 0.001) among all parameters assessed (1,928  789 AU
vs. 5,111  2,409 AU).
events
death, AVR, nonfatal MI,
heart failure requiring
nt hospitalization
AVC predictor of cardiac events (HR: 1.09; 95% CI: 1.04–1.15)
per 100-AU increment
AVCS $723 (the median value) had signiﬁcantly worse
outcomes than those with AVCS <723 (p < 0.0001)
ty Severe AVC (deﬁned as $1,274 AU in women and $2,065 AU
in men) was an independent predictor of overall mortality
(HR: 1.71; 95% CI: 1.12 to 2.62; p ¼ 0.01)
VR ¼ aortic valve replacement; CI ¼ conﬁdence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction.
FIGURE 4 Relationship Among Baseline Disease Severity, Disease Activity, and Disease Progression
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(A) Studies using PET have demonstrated that calciﬁcation activity in the valve (as measured using 18F-ﬂuoride) steadily increases with disease severity. As a conse-
quence, activity is highest in those with the most advanced disease, and a good correlation exists between 18F-ﬂuoride activity and the baseline CT calcium score (79).
(B) Subsequently, this increased calciﬁcation activity appears to translate to more rapid disease progression (as measured by both echocardiography and CT calcium
scoring) in patients with the most advanced forms of aortic stenosis (78). Reproduced with permission from Nguyen V, et al. (78). AS ¼ aortic stenosis; AU ¼ Agatston
units; CT ¼ computed tomography.
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570prediction of both disease progression and adverse
clinical events. It is potentially complementary to
standard echocardiographic assessments and may
have some advantages, most notably that it is not
dependent on cardiac loading conditions, geometric
assumptions, or on the presence of other cardiovas-
cular conditions, such as mitral regurgitation and
hypertension. Further work is now required to vali-
date the proposed thresholds in other patient pop-
ulations and to explain the observed sex differences.
POSITRON EMISSION TOMOGRAPHY
PET is a noninvasive imaging technique that allows
the activity of speciﬁc biological processes to be
measured in vivo within speciﬁc structures, including
the aortic valve. In principle, any disease process can
be evaluated dependent on the availability of a suit-
able tracer. To date, studies in aortic stenosis have
largely investigated tracers targeted to inﬂammation
(18F-ﬂuorodeoxyglucose [FDG]) and calciﬁcation
(18F-ﬂuoride), aiming to establish the relative contri-
butions of these processes to disease development
and progression (79–81).
INFLAMMATION. The PET radiotracer 18F- FDG is a
glucose analog taken up by metabolically active cells.
Because it is unable to proceed through the glycolyticpathway, it accumulates within these cells without
further metabolism. Because vascular macrophages
have higher metabolic requirements than the sur-
rounding tissue, 18F-FDG has emerged as a useful
tool for the identiﬁcation of vascular inﬂammation.
Uptake in regions of carotid atheroma correlates well
with macrophage density (mean percent staining of
CD68-positive cells, r ¼ 0.85; p < 0.0001) (82,83) and
is modiﬁable with statin therapy (84).
To determine the contribution of inﬂammation to
the pathogenesis of calciﬁc aortic stenosis, we per-
formed PET imaging of the aortic valve using 18F-
FDG in a prospective cohort of 121 patients with the
full spectrum of calciﬁc aortic valve disease
(including 20 patients with aortic sclerosis and 20
control subjects) (79). 18F-FDG activity was increased
in patients with aortic stenosis compared with con-
trol subjects (1.58  0.21 vs. 1.30  0.13; p < 0.001),
and this correlated with disease severity (79). How-
ever, unlike previous work on carotid atheroma, the
18F-FDG signal did not correlate with macrophage
(CD68) staining, raising the possibility that 18F-FDG
may not be acting as a marker of inﬂammation in the
calcifying aortic valve, but instead might reﬂect
glucose utilization by other metabolically-active
cells, such as myoﬁbroblasts or differentiated oste-
ogenic cells (77).
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571CALCIFICATION. 18F-ﬂuoride has been used safely as
a bone tracer for more than 40 years, exchanging
with hydroxyl groups in hydroxyapatite to form ﬂu-
oroapatite. Similar hydroxyl bonds are also present in
the different forms of calcium in the vasculature
(including hydroxyapatite and amorphous calcium)
so that 18F-ﬂuoride binding acts as a marker of
vascular calciﬁcation. In particular, the binding of
18F-ﬂuoride to calcium appears to be critically
dependent upon the surface area of calcium ortho-
phosphate available for incorporation. 18F-ﬂuoride,
therefore, preferentially binds regions of newly
developing microcalciﬁcation (beyond the resolution
of CT), which have a nanocrystalline structure and
very high surface area, rather than to large, estab-
lished, macroscopic deposits, where much of the
calcium is internalized and, therefore, not available
for binding (85). On this basis, increased 18F-ﬂuoride
uptake is observed in regions of actively developing
calciﬁcation, demonstrating a close association with
alkaline phosphatase staining (r ¼ 0.65; p ¼ 0.04) on
excised aortic valve tissue removed at the time of
surgery (77).
When the same cohort of 121 patients was imaged
with 18F-ﬂuoride, the observed PET signal in the
aortic valve was stronger and more clearly demar-
cated than was seen with 18F-FDG (Figure 3). More-
over, the spatial distribution of the 18F-ﬂuoride signal
was often discrete from the macroscopic calcium de-
posits identiﬁed by CT, indicating that 18F-ﬂuoride
uptake provides distinct, but complementary infor-
mation to CT alone. Uptake was increased in patients
with aortic stenosis compared with healthy control
subjects (2.87  0.82 vs. 1.55  0.17; p < 0.001) and
correlated with disease severity (r ¼ 0.73; p < 0.001)
(79). Indeed, the highest calciﬁcation activity, as
measured using this tracer, was observed in patients
with the most advanced disease (Figure 4A). Again,
this supports the hypothesis that calciﬁcation begets
calciﬁcation activity in aortic stenosis and would
explain the rapid rates of disease progression in those
at the severe end of the spectrum.
When patients were recalled for repeat CT calcium
scoring of the valve at 1 and 2 years, new calcium
could be observed in the areas of increased 18F-
ﬂuoride activity seen on the baseline scan (Figure 5).
As a consequence, a close correlation was observed
between the baseline valvular 18F-ﬂuoride uptake and
the progression of the aortic valve CT calcium score
(r ¼ 0.80; 95% CI: 0.69 to 0.87; p < 0.001), with PET
appearing to offer some additional predictive infor-
mation over and above the baseline calcium score.
Moreover, this translated into an ability to predict
valve hemodynamic progression, with moderatecorrelations also observed between 18F-ﬂuoride ac-
tivity and the mean (r ¼ 0.32; 95% CI: 0.13 to 0.50;
p ¼ 0.001) and peak (r ¼ 0.32; 95% CI: 0.12 to 0.49;
p ¼ 0.002) aortic valve gradients (67). Finally, after a
median of 1,526 days of follow-up, 18F-ﬂuoride
emerged as a prognostic marker serving as an inde-
pendent predictor of the combined endpoint of aortic
valve replacement and cardiovascular mortality
(hazard ratio: 1.55; 95% CI: 1.33 to 1.81, after adjusting
for age and sex; p < 0.001).
In summary, these data highlight the potential
application of 18F-ﬂuoride as an immediate, nonin-
vasive measure of disease activity in aortic stenosis
with the ability to predict its natural history. The
instantaneous readout of disease activity holds
particular promise in assessing the early efﬁcacy of
novel therapeutic agents, in which treatment effects
are likely to be discernible over a much shorter time
period than could be resolved using clinical end-
points, echocardiography, or CT.
Should 18F-ﬂuoride PET be used as a clinical tool?
Although PET performed well in predicting the nat-
ural history of aortic stenosis, the far simpler tech-
nique of CT calcium scoring appeared to provide
almost equivalent prediction of disease progression.
Moreover, in agreement with the work by Clavel et al.
(72,73), CT again provided incremental prediction of
clinical outcomes to even echocardiographic assess-
ments of hemodynamic severity. Whilst supporting a
greater role for CT, this would argue against the use of
PET in the routine clinical arena. It also raises the
question as to why an anatomic measure of calcium
burden can provide such effective prediction of
future disease progression? We believe that this
reﬂects the close association between calciﬁcation
activity in the valve (as assessed by 18F-ﬂuoride) and
the baseline calcium score (r ¼ 0.80; p < 0.001), and
provides further evidence for the model of calcium
begetting further calcium formation in the propaga-
tion phase of the disease (Figure 1). Regardless of the
mechanism, the close link between calcium burden
and calciﬁcation activity in the valve ensures that
even the simplest methods of aortic valve calcium
burden provide a surrogate of disease activity and
effective prediction of disease progression.
The imaging techniques described previously allow
us to image calciﬁcation in the valve in progressive
detail. They have helped to conﬁrm the important
role that calciﬁcation plays in driving aortic stenosis
and have allowed us to both characterize the severity
of disease and to better predict disease progression.
We anticipate that CT calcium scoring will assume a
greater clinical role, whereas PET will prove a
powerful research tool, in particular as an endpoint
FIGURE 5 Change in Aortic Valve CT Calcium Score and 18F-Sodium Fluoride PET Activity After 1 Year
Baseline CT calcium scores (left) for patients 1 and 2 (top and bottom). Fused coaxial 18F-ﬂuoride PET-CT scans (middle) show ﬂuoride uptake in red and yellow.
The 1-year follow-up (right) suggests that the baseline PET signal predicts the spatial distribution of subsequent macrocalciﬁcation (77). Abbreviations as in Figure 3.
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572in clinical trials assessing the efﬁcacy of novel,
potentially disease-modifying therapies. Indeed,
18F-ﬂuoride PET has the potential to provide both
mechanistic insights and a far more rapid readout of
efﬁcacy than CT calcium scoring or echocardiographic
parameters.
POTENTIAL NOVEL
DISEASE-MODIFYING THERAPIES
As our understanding of the pathophysiology of aortic
stenosis has improved, the key role that calciﬁcation
plays in driving disease progression has led us away
from targeting inﬂammation and lipid deposition and
toward therapies capable of directly halting valve
calciﬁcation (86). How might this be achieved? The
close association between disorders of skeletal bone
metabolism and increased calciﬁcation in the vascu-
lature offers a potential starting point. A growing
body of pre-clinical and clinical data indicates that
treatments for osteoporosis, such as bisphosphonatesand denosumab, can reduce vascular calciﬁcation and
that these agents hold considerable promise as novel
therapies for aortic stenosis (87).
BISPHOSPHONATES. Bisphosphonates are inhibitors
of osteoclast-mediated bone resorption, are well
tolerated in elderly patients, and have been widely
used for the treatment of osteoporosis (88). Inter-
estingly, bisphosphonates also have important car-
diovascular effects, demonstrating a consistent
reduction in calciﬁcation of the vasculature and the
aortic valve (87,89,90). This, in part, appears to be a
consequence of their inhibition of bone resorption,
which results in reduced release of calcium and
phosphate into the circulation and, therefore, in the
reduced systemic availability of these procalciﬁc
substances (Figure 2B) (87). However, bisphospho-
nates also appear to exert direct anticalciﬁc effects on
the aortic valve tissue itself. They reduce the pro-
duction of IL-1b, IL-6, and TNF-a (key inﬂammatory
cytokines implicated in the early stages of aortic
stenosis [91]) and inhibit the secretion of matrix
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573metalloproteinases 2 and 9, which remodel the valve
as aortic stenosis progresses (Figure 1) (92,93). More-
over, nitrogen-containing bisphosphonates act as
inorganic pyrophosphate analogs (48), which, as dis-
cussed, have powerful anticalciﬁc properties in the
vasculature. Finally, bisphosphonates attenuate the
differentiation of aortic valve myoﬁbroblasts into
cells with an osteogenic phenotype (94), the key step
in triggering the propagation phase of aortic stenosis
(86). In combination, these data offer support for
bisphosphonates as a treatment strategy for aortic
stenosis that is increasingly being supported by
observational clinical data. A recent analysis of 3,710
women in the MESA (Multi-Ethnic Study of Athero-
sclerosis) indicated that bisphosphonate use was
associated with less valvular and vascular calciﬁca-
tion in older women (users vs. nonusers: aortic valve
ring calcium 38% vs. 59%; p < 0.0001) (95). Other
studies appear to support these ﬁndings with a direct
beneﬁcial effect of these drugs on echocardiographic
measures of aortic stenosis progression (96–98), as
well as reducing valvular calciﬁcation in patients with
renal failure and amongst those with bioprosthetic
valves (87,99). Although encouraging, such retro-
spective, observational studies are prone to bias,
cannot assess cause-and-effect, have provided con-
ﬂicting results (100), and are confounded by the un-
derlying effects of the osteoporosis for which these
agents were prescribed. Indeed, the true effect of
bisphosphonates in aortic stenosis will only become
clear within the context of a randomized controlled
trial (101).
DENOSUMAB. As discussed, the OPG/RANK/RANKL
axis appears to play a pivotal role in aortic valve
calciﬁcation and may provide an explanation for the
link between osteoporosis and increased vascular
calciﬁcation. It, therefore, represents an attractive
therapeutic target for reducing vascular calciﬁcation
(Figure 2C). Denosumab is a human monoclonal anti-
body to RANKL that prevents its binding to RANK,
thereby recapitulating the actions of OPG. In a trial of
7,868 post-menopausal women with osteoporosis,
denosumab increased bone mineral density and
reduced vertebral fracture rates by 68% over a 3-year
period (102). Importantly, denosumab was extremely
well tolerated, with very few adverse side effects and
no major excess of adverse events. Given the central
regulatory role of the OPG/RANK/RANKL system in
vascular and aortic valve calciﬁcation, denosumab
also holds considerable promise as a novel treatment
for aortic stenosis. Again, this is supported by pre-
clinical data, with denosumab halving the aortic
calciﬁcation observed in a murine model of osteopo-
rosis (103). Interestingly, in the same study, thisreduction was closely associated with inhibited
bone resorption from the skeleton, indicating
that the cardiovascular effects of denosumab are,
like bisphosphonates, in part related to reduced
calcium and phosphate release from bone into the
circulation.
FUTURE PERSPECTIVES
Bisphosphonates and denosumab hold promise as
novel treatments for aortic stenosis and are currently
being investigated as part of an ongoing randomized
control trial (NCT02132026) (104). However, even if
these prove ineffective, we believe that future treat-
ments should still be directed at the propagation
phase and at breaking the self-perpetuating cycle of
valvular injury, osteogenic differentiation, and cal-
cium deposition. As discussed, a rapidly expanding
list of signaling pathways and molecular processes
governing the pathogenesis of aortic stenosis have
been elucidated, uncovering many additional targets
at different phases of the disease; these are discussed
in the following paragraphs. In addition, further
investigation is warranted to assess whether poten-
tially pro-calciﬁc drugs, including calcium supple-
ments and coumarins, should be avoided in patients
with aortic stenosis.
Ultimately, many of the procalciﬁc pathways in
the valve appear to converge on the up-regulation
of osteogenic differentiation factors (e.g., BMP-2,
Wnt-b-catenin) that establish osteoblast-like func-
tion within the valve. These factors therefore pro-
vide an attractive therapeutic strategy, although,
given the overlap in factors governing calciﬁcation
in the bone and the valve, the major challenge will
be to slow aortic stenosis progression without
compromising bone health. One potential approach
would be to target the upstream cytokines that
activate BMP, such as using inhibitors of IL-6 or
TNF-a (as already used in rheumatoid arthritis).
However, once again, it remains unclear whether
targeting inﬂammation will be effective in the
propagation phase once the procalciﬁc processes
have become established. Targeting ectonucleoti-
dases may be more effective, given their apparently
central role in establishing the positive feedback
loop by which calcium begets calcium. Ectonucleo-
tidase inhibitors have already been tested in the
warfarin rat model and have been shown to prevent
the development of calciﬁc aortic valve disease
(105). Interest also surrounds P2Y2 receptor antago-
nists as a means of reducing VIC apoptosis and the
calciﬁcation that this induces. Therapeutic admin-
istration of fetuin-A, or a mimetic of MGP, could
CENTRAL ILLUSTRATION The Pathogenesis of Aortic Stenosis in 2 Stages
Endothelial injury
Infiltration of oxidized lipids and inflammatory cells into aortic valve
Lipoprotein(a) and 
oxidized low-density
lipoprotein cholesterol 
Differentiation of valve interstitial cells
to osteoblast-like cells
Deposition of
collagen and bone-
related proteins
Mechanical stress, 
injury and apoptosis Micro-calcification
Macro-calcification
Progressive valve obstruction
Cholesterol
reduction with:
• Lipoprotein(a) 
inhibitors 
• Statins
Calcification
reduction with:
• Bisphosphonates
• Denosumab
• Ectonucleotidase
and ACE inhibitors 
• 18F-Fluoride PET
to investigate 
micro-calcification 
activity in the valve
• Computed 
Tomography (CT) 
Calcium scoring
to assess the burden
of macroscopic 
calcium in the valve
• Echocardiography
to assess valve 
obstruction severity
• Potentially 18F-FDG 
Positron Emission 
Tomography (PET)
to investigate 
inflammation
PATHOPHYSIOLOGY
Ph
as
e 
1:
 In
iti
at
io
n
Ph
as
e 
2:
 S
el
f p
ro
pa
ga
tin
g 
lo
op
TREATMENT OPTIONSIMAGING OPTIONS
Macrophages, mast cells 
and T-lymphocytes
Pawade, T.A. et al. J Am Coll Cardiol. 2015; 66(5):561–77.
Initiation phase: similar to the early stages of atherosclerosis, endothelial injury facilitates the inﬁltration of oxidized lipids and inﬂammatory cells into the
valve and the release of proinﬂammatory mediators. These trigger the very early stages of valve calciﬁcation so that the incidence of aortic stenosis closely
relates to traditional cardiovascular risk factors for atherosclerosis. Propagation phase: these proinﬂammatory processes subsequently induce VICs to
undergo osteogenic differentiation. The VICs ﬁrst lay down a collagen matrix and other bone-related proteins before producing calcium (7,8). Calciﬁcation
of the valve induces compliance mismatch, resulting in increased mechanical stress, injury, and apoptosis (9), which triggers further calciﬁcation (10).
Hence, a self-perpetuating cycle of calciﬁcation, valve injury, and osteogenic activation is established that drives the propagation phase of the disease. As a
consequence, disease progression in aortic stenosis more closely relates to procalciﬁc factors, rather than lipid inﬁltration or inﬂammation. The different
stages of calciﬁcation in the valve can be imaged using 18F-Fluoride PET (newly developing microcalciﬁcation) and CT calcium scoring (macroscopic calciﬁc
deposits). Given the central role of calciﬁcation in the propagation phase of aortic stenosis, it is perhaps unsurprising that these imaging techniques provide
important information with respect to prognosis and disease progression. Moreover, calciﬁcation represents an important potential therapeutic target, with
the use of drugs, such as denosumab and bisphosphonates, to interrupt the vicious cycle of calciﬁcation that drives progressive narrowing of the valve.
ACE ¼ angiotensin-converting enzyme; CT ¼ computed tomography; FDG ¼ ﬂuorodeoxyglucose; PET ¼ positron emission tomography; VIC ¼ valvular
interstitial cell.
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574simultaneously target multiple pathways thought to
drive valvular calciﬁcation.
The ability of lipoprotein(a)-lowering therapies to
modify aortic stenosis disease progression is likely to
form the basis of a future clinical trial. Given the
failure of the statin trials, it will be of great interest to
determine whether a more targeted lipid intervention
will have greater success in reducing diseaseprogression in the propagation phase (106). On the
basis of the apparent contribution of the RAS to the
initiation of aortic stenosis, it is also not unreasonable
to consider ACE inhibitors, or even selective AT1 re-
ceptor antagonists or novel renin inhibitors, as novel
treatments. Indeed, these agents are also likely to
have a beneﬁcial effect with respect to hypertension
and left ventricular remodeling in aortic stenosis,
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575given the role that the RAS system also plays in
driving myocardial hypertrophy, ﬁbrosis, and the
transition to heart failure.
CONCLUSIONS
Aortic stenosis is a common condition that is set to
become an increasing health care burden. We lack
effective medical therapies capable of slowing its
relentless progression toward major surgery or
adverse events. Recent insights into the pathophysi-
ology of aortic stenosis have indicated that although
lipid and inﬂammation may be important in estab-
lishing the disease (initiation phase), it is the
self-perpetuating processes of calciﬁcation that are
predominantly responsible for driving diseaseprogression (propagation phase) (Central Illustration).
On this basis, imaging modalities capable of quanti-
fying aortic valve calciﬁcation will be best placed to
predict its natural history, whereas novel anticalciﬁc
therapies hold major promise as methods of treat-
ment. Randomized controlled trials of such agents,
perhaps using imaging endpoints such as CT calcium
scoring and 18F-ﬂuoride PET activity, are now
required to establish their early efﬁcacy.
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